Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand-Reference-Cited by-同舟云学术

Immunogenicity of the BNT162b2 COVID-19 vaccine as a third dose (booster) following two doses of different primary series regimens in Thailand

Published:2022-08-03 Issue:7 Volume:116 Page:395-397
ISSN:2047-7724
Container-title:Pathogens and Global Health
language:en
Short-container-title:Pathogens and Global Health

Author:

Wanlapakorn Nasamon¹,Suntronwong Nungruthai¹,Kanokudom Sitthichai¹,Assawakosri Suvichada¹,Nilyanimit Pornjarim¹,Yorsaeng Ritthideach¹,Chansaenroj Jira¹,Poovorawan Yong¹²

Affiliation:

1. Center of Excellence in Clinical Virology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

2. FRS(T), the Royal Society of Thailand, Sanam Sueapa, Dusit, Bangkok, Thailand

Funder

the National Research Council of Thailand

the Health Systems Research Institute

the Center of Excellence in Clinical Virology of Chulalongkorn University

King Chulalongkorn Memorial Hospital

MK Restaurant Group

the Second Century Fund Fellowship of Chulalongkorn University

Publisher

Informa UK Limited

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Medicine,Microbiology,Parasitology

Link

https://www.tandfonline.com/doi/pdf/10.1080/20477724.2022.2108646

Reference8 articles.

1. Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data

2. Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination

3. Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine

4. Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination

5. Effects of boosted mRNA and adenoviral-vectored vaccines on immune responses to omicron BA.1 and BA.2 following the heterologous CoronaVac/AZD1222 vaccination

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina;Frontiers in Immunology;2024-05-14

2. Evaluation of Anti-S1 IgA Response to Different COVID-19 Vaccination Regimens;Vaccines;2023-06-19

3. Comparison of the reactogenicity and immunogenicity between two‐dose mRNA COVID‐19 vaccine and inactivated COVID‐19 vaccine followed by an mRNA vaccine in children aged 5−11 years;Journal of Medical Virology;2023-04-27

4. The Fourth Dose of mRNA COVID-19 Vaccine Following 12 Different Three-Dose Regimens: Safety and Immunogenicity to Omicron BA.4/BA.5;Vaccines;2023-03-01

5. The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5;2023-01-19